Drug Profile


Alternative Names: PO-BB0209; REOLYSIN; Reovirus; Reovirus - Oncolytics Biotech; Reovirus anticancer; Reovirus antitumour; Reovirus Serotype 3 - Dearing Strain; Respiratory Enteric Orphan virus; Wild-type reovirus

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Oncolytics Biotech
  • Developer Mayo Clinic; National Cancer Institute (Canada); National Cancer Institute (USA); Oncolytics Biotech; University of Leeds; University of Southern California
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Peritoneal cancer; Ovarian cancer; Gastric cancer; Pancreatic cancer; Fallopian tube cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Head and neck cancer
  • Phase II Brain cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
  • Phase I/II Glioma
  • Phase I Multiple myeloma; Solid tumours
  • Preclinical Hepatocellular carcinoma; Viral hepatitis

Most Recent Events

  • 06 Feb 2017 Oncolytics plans a clinical trial for Glioblastoma (Combination therapy) in United Kingdom (IV)(ISRCTN70044565) (EudraCT2016-001632-35)
  • 01 Feb 2017 Oncolytics withdraws a phase I trial prior to enrolment for Bladder cancer (Late-stage disease, Metastatic disease, Combination therapy, Neoadjuvant therapy) in USA (NCT02723838) due to company's reprioritised clinical plans to focus on later-stage studies
  • 06 Jan 2017 Myeloma UK, Oncolytics Biotech, Celgene Corporation and University of Leeds plan the phase I MUK eleven trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in United Kingdom (IV, Infusion) (NCT03015922)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top